Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | HRH2 | P25021 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | BCHE | P06276 | 5/20 | 0.40 |
| ▸ | ACHE | P22303 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.40 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.40 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.40 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13639510 | 0.79 | HTR2A (0.50) | HTR2AHTR2CHTR2BHRH2HRH3 | |
| SCHEMBL24819490 | 0.76 | ALDH1A1 (0.46) | HRH2HRH3LMNAMAPK10HSD17B10 | |
| SCHEMBL12677180 | 0.75 | LMNA (0.49) | HTR2AHTR2CHTR2BHRH2HRH3 | |
| SCHEMBL1101906 | 0.75 | NPSR1 (0.50) | HRH2HRH3LMNAHSD17B10KDM4E | |
| SCHEMBL9821295 | 0.73 | LMNA (0.54) | HTR2AHTR2CHTR2BLMNATHRB | |
| SCHEMBL29881705 | 0.73 | LMNA (0.54) | HTR2AHTR2CHTR2BLMNATHRB | |
| SCHEMBL4134361 | 0.72 | ALDH1A1 (0.52) | HRH2HRH3LMNAMAPK10HSD17B10 | |
| SCHEMBL12426082 | 0.71 | SMN1; SMN2 (0.40) | HTR2AHTR2CHTR2BKDM4EBCHE | |
| SCHEMBL28151465 | 0.70 | KDM4E (0.50) | LMNAHSD17B10KDM4EBCHEACHE | |
| SCHEMBL9558677 | 0.70 | MAPT (0.58) | HSD17B10KDM4EACHEALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206161-B2 | Bridged bicyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150126514-A1 | BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | MIDCAP FINANCIAL TRUST | 2015-05-07 | — | — | US | disclosed |
| US-8933080-B2 | Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140128400-A1 | BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-8658669-B2 | Bridged bicyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8431594-B2 | Bridged bicyclic heteroaryl substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20130018051-A1 | BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20110105512-A1 | BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105512-A1 | BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | ERBB2, AXL, ERBB3 | HTR2A 2210/4885HTR2C 1484/4885HTR2B 2456/4885 |
| US-20140128400-A1 | BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, ERBB2, TYRO3 | HTR2A 2321/4885HTR2C 1717/4885HTR2B 2290/4885 |
| US-20150126514-A1 | BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, ERBB2, TYRO3 | HTR2A 2321/4885HTR2C 1717/4885HTR2B 2290/4885 |
| US-20130018051-A1 | BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, ERBB2, TYRO3 | HTR2A 2321/4885HTR2C 1717/4885HTR2B 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.